Authors
Latest:
Virtual Medical Affairs Audits: A Viable AlternativeVirtual audits proving to be beneficial post-COVID despite continuing challenges.
Latest:
The Case for Market Access...Early and OftenIndustry veteran Ken Abreu makes the case for approaching market access very early in the process, and elucidates why it's so important.
Latest:
12 Healthcare Provider Pharma Social Media Predictions for 2022Social Media is omnipresent and harnessing its power should be high on lists of healthcare providers (HCPs). How do they get their message out to reach the right people at the right time and how do they distinguish themselves from their competitors? Here are 12 predictions and factors for 2022.
Latest:
Seven Lessons I Learned Working at a Biotech StartupHow early stage can help set you up for big stage.
Latest:
The Effects of Ransomware on Science & Its ResearchersLife sciences companies a likely targets of these kinds of attacks.
Latest:
Exploring the “Other” End-User – HCPs and the Challenges to Adoption of Machine Learning-based Digital SolutionsWebinar Date/Time: Mon, Dec 5, 2022 2:00 PM EST
Latest:
Using Real-World Data to Examine Long-Term Safety and Effectiveness in Extension StudiesLeveraging RWD can lessen the strain normally put on investigators and sites.
Latest:
Making Medication Assistance Program Solutions Work for YouHow technology can maximize use of manufacturer copay and patient assistance programs.
Latest:
Navigating the Future: Key Market Access Trends to Watch in ’24Five emerging themes likely to impact pharma in the new year.
Latest:
Capitalizing On Collaboration and Confidence: Survey Insights and Expectations For Biotech in 2024Dr. Chris Smyth, president of ICON Biotech, discusses emerging trends in the biotech space.
Latest:
Real-Time Measurement of EPA Regulated HON Compounds and Environmental Pollutants Using SIFT-MSThis application note summarizes key SIFT-MS results presented in a peer reviewed article entitled “Unreported VOC Emissions from Road Transport Including from Electric Vehicles.” Learn how the Wolfson Atmospheric Chemistry Laboratory at the University of York used SIFT-MS for VOC analysis in its platform to experimentally verify that motor vehicle screen wash is a significant unreported source of VOC emissions (especially for ethanol and methanol).
Latest:
New Horizons for Patient-Centric Drug DeliveryOral solid dose formulations (OSD) continue to lead the market as a preferred dosage form. To gain better insight into drug dose delivery technology trends, Laura Child spoke to leaders from five top contract development and manufacturing organizations to find out what is on the horizon for patient-centric drug delivery.
Latest:
Biopharma and ESG: Key Strategies for Companies, Meaningful Changes to CommunitiesNew regulations set stage for updated ESG considerations.
Latest:
Lessons Learned on the Art and Science of Product CommercializationInsight that can help smaller biotech companies prepare for commercialization in the world of big pharma.
Latest:
Investing for Success: Finding the Right Launch BalanceChallenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
Latest:
2021 Projections on the Future of Patient Engagement in PharmaOn the back of COVID-19, pharma has an opportunity to radically rethink a long-held reluctance to build end-customer relationships into their core business models, writes Simon Bates and Valerie Phillips.
Latest:
Commercial Sustainability of Pharmaceutical Innovations for PandemicsAssessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Latest:
Developing a Product Launch Strategy for an Orphan DrugCommercializing an orphan drug can be challenging, however, using a framework and a checklist that incorporates the right elements can prove beneficial.
Latest:
Securities Litigation Arising from Alzheimer's Drug TreatmentsThe legal challenges surrounding Biogen’s Aduhelm and Cassava Sciences’ simufilam underscore the ongoing difficulties in Alzheimer's drug development, leading to securities litigation over allegedly misleading statements about trial results and commercialization efforts.
Latest:
How AI is Revamping the Product LaunchNew technology is allowing teams to analyze data at faster rates and make decisions much sooner than they previously could.
Latest:
Rx Power Struggle: How Pharma can Flip the PBM ScriptThe industry holds the key to true change to the drug access landscape.
Latest:
Validating COAs: Key Steps for Accurate and Reliable Clinical Trial DataWith the increasing adoption of COAs, the importance of standardization across training, collection, and implementation to ensure high quality and consistent data collection has become apparent in recent decades.
Latest:
How Technology Can be Used to Improve AdherenceComprehensive dosage monitoring of topical treatments for mild to moderate psoriasis.
Latest:
Turning COVID-19 Era Regulatory Efficiencies into Long-term Business Growth and InnovationCOVID-19 pandemic sets new standards for life sciences industry.
Latest:
Understanding Healthcare Access Barriers: Industry Trends and the Patient Assistance ApproachWebinar Date/Time: Thu, Mar 28, 2024 2:00 PM EDT
Latest:
The Interplay Between COVID-19 Pandemic and NCD EpidemicAmid attention on coronavirus, efforts to address the burden of non-communicable diseases are at a critical juncture.
